On the heels of a global R&D reorganization, Novo Nordisk outlines 250 US job cuts

Novo Nordisk is slashing 250 US jobs in an ongoing reorganization of the business.

MedWatch reported that the pharma company is whacking 100 back office jobs while eliminating another 150 “educators” involved in its diabetes business.